↓ Skip to main content

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL…

Overview of attention for article published in Breast Cancer Research, September 2019
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Published in
Breast Cancer Research, September 2019
DOI 10.1186/s13058-019-1186-0
Pubmed ID
Authors

Tejal A. Patel, Joe E. Ensor, Sarah L. Creamer, Toniva Boone, Angel A. Rodriguez, Poly A. Niravath, Jorge G. Darcourt, Jane L. Meisel, Xiaoxian Li, Jing Zhao, John G. Kuhn, Roberto R. Rosato, Wei Qian, Anna Belcheva, Mary R. Schwartz, Virginia G. Kaklamani, Jenny C. Chang

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 21%
Student > Ph. D. Student 3 13%
Student > Master 3 13%
Researcher 2 8%
Unspecified 2 8%
Other 4 17%
Unknown 5 21%
Readers by discipline Count As %
Medicine and Dentistry 8 33%
Pharmacology, Toxicology and Pharmaceutical Science 4 17%
Unspecified 2 8%
Nursing and Health Professions 1 4%
Agricultural and Biological Sciences 1 4%
Other 2 8%
Unknown 6 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 September 2019.
All research outputs
#8,453,188
of 15,807,382 outputs
Outputs from Breast Cancer Research
#968
of 1,652 outputs
Outputs of similar age
#117,841
of 265,468 outputs
Outputs of similar age from Breast Cancer Research
#1
of 1 outputs
Altmetric has tracked 15,807,382 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,652 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 10.0. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,468 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them